Incidence and Risk of QTc Interval Prolongation among Cancer Patients Treated with Vandetanib: A Systematic Review and Meta-analysis

BACKGROUND: Vandetanib is a multikinase inhibitor that is under assessment for the treatment of various cancers. QTc interval prolongation is one of the major adverse effects of this drug, but the reported incidence varies substantially among clinical trials. We performed a systematic review and met...

Descripción completa

Detalles Bibliográficos
Autores principales: Zang, Jiajie, Wu, Shunquan, Tang, Lei, Xu, Xudong, Bai, Jie, Ding, Caicui, Chang, Yue, Yue, Long, Kang, Enming, He, Jia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3281826/
https://www.ncbi.nlm.nih.gov/pubmed/22363427
http://dx.doi.org/10.1371/journal.pone.0030353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3281826/
https://www.ncbi.nlm.nih.gov/pubmed/22363427
http://dx.doi.org/10.1371/journal.pone.0030353

Ejemplares similares